Compositions and methods for providing hematopoietic function without HLA matching

Abstract

The present invention relates to methods and compositions for providing hematopoietic function in immunodeficient human patients, by selecting an expanded human umbilical cord blood stem / progenitor cell sample without taking into account the HLA-type of the expanded human cord blood stem / progenitor sample or the HLA-type of the patient; and administering the selected expanded human cord blood stem / progenitor cell sample to the patient. Methods for obtaining the expanded human cord blood stem / progenitor cell samples, banks of frozen expanded human cord blood stem / progenitor cell samples, and methods for producing such banks are also provided herein.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of U.S. application Ser. No. 13 / 640,297 filed Dec. 21, 2012, which is a national phase of International Application No. PCT / US2011 / 031953, filed Apr. 11, 2011, which claims benefit of U.S. Provisional Application No. 61 / 322,544, filed Apr. 9, 2010, each of which are incorporated by reference herein in their entirety.STATEMENT OF GOVERNMENT SUPPORT[0002]This invention was made with government support under HHS010020080064C awarded by the Department of Health and Human Services and HL101844 awarded by the National Institutes of Health. The government has certain rights in the invention.FIELD OF THE INVENTION[0003]The present invention relates to methods and compositions for providing hematopoietic function to human patients in need thereof, by selecting an expanded human umbilical cord blood stem / progenitor cell sample without taking into account the HLA-type of the expanded human cord blood stem cell / prog...

AI Technical Summary

Benefits of technology

[0028]In one embodiment, the expanded human cord blood stem cell sample of the present invention has been subjected to an expansion technique that has been shown to result in an at least 50-fold increase in hematopoietic stem cells or hematopoietic stem and progenitor cells in an aliquot of a human cord blood stem cell sample subjected to the expansion technique, relative to an aliquot of the human cord blood stem cell sample prior to being subjected to the expansion technique. The hematopoietic stem cells or the hematopoietic stem and progenitor cells can be positive for one or more of the following cell surface markers expressed in increased levels on hematopoietic stem cells or hematopoietic stem and progenitor cells, relative to other types of hematopoietic cells: CD34, CD43, CD45RO, CD45RA, CD59, CD90, CD109, CD117, CD133, CD166, and HLA DR and / or negative for Lin and / or CD38 cell surface markers. Preferably, the hematopoietic stem cells or hematopoietic stem and progenitor cells are positive for one or more of CD34, CD133 or CD90 cell surface markers. Preferably, the expanded human cord blood stem cell sample of the present invention has been subjected to an expansion technique that has been shown (i) to result in an at least 50-fold increase in CD34+ cells in an aliquot of a human cord blood stem cell sample subjected to the expansion technique, relative to an aliquot of the human cord blood stem cell sample prior to being subjected to the expansion technique; or (ii) to increase the number of SCID repopulating cells in a human cord blood stem cell sample subject to the expansion technique, relative to the human cord blood cell stem cell sample prior to being subject to the expansion technique.

Problems solved by technology

Of particular concern is prolonged neutropenia, which results in a significant risk of infection despite improved antimicrobial therapy and increases morbidity and mortality.

They may be the cause of organ transplant rejections.

Once the stem cell differentiates into a myeloid progenitor cell, its progeny cannot give rise to cells of the lymphoid lineage, and, similarly, lymphoid progenitor cells cannot give rise to cells of the myeloid lineage.

Images